158 related articles for article (PubMed ID: 26919240)
1. miR-342 overexpression results in a synthetic lethal phenotype in BRCA1-mutant HCC1937 breast cancer cells.
Crippa E; Folini M; Pennati M; Zaffaroni N; Pierotti MA; Gariboldi M
Oncotarget; 2016 Apr; 7(14):18594-604. PubMed ID: 26919240
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.
Matamala N; Vargas MT; González-Cámpora R; Arias JI; Menéndez P; Andrés-León E; Yanowsky K; Llaneza-Folgueras A; Miñambres R; Martínez-Delgado B; Benítez J
Oncotarget; 2016 Apr; 7(15):20068-79. PubMed ID: 26933805
[TBL] [Abstract][Full Text] [Related]
3. Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers.
Fkih M'hamed I; Privat M; Ponelle F; Penault-Llorca F; Kenani A; Bignon YJ
Cell Oncol (Dordr); 2015 Dec; 38(6):433-42. PubMed ID: 26392359
[TBL] [Abstract][Full Text] [Related]
4. miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer.
Crippa E; Lusa L; De Cecco L; Marchesi E; Calin GA; Radice P; Manoukian S; Peissel B; Daidone MG; Gariboldi M; Pierotti MA
PLoS One; 2014; 9(1):e87039. PubMed ID: 24475217
[TBL] [Abstract][Full Text] [Related]
5. Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
Guney Eskiler G; Cecener G; Egeli U; Tunca B
Pharm Res; 2018 Sep; 35(11):218. PubMed ID: 30255456
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
7. miR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival.
Zavala V; Pérez-Moreno E; Tapia T; Camus M; Carvallo P
Cancer Biomark; 2016; 16(1):99-107. PubMed ID: 26835710
[TBL] [Abstract][Full Text] [Related]
8. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
9. Integration of BRCA1-mediated miRNA and mRNA profiles reveals microRNA regulation of TRAF2 and NFκB pathway.
Tanic M; Zajac M; Gómez-López G; Benítez J; Martínez-Delgado B
Breast Cancer Res Treat; 2012 Jul; 134(1):41-51. PubMed ID: 22167321
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies.
Martinez-Outschoorn UE; Balliet R; Lin Z; Whitaker-Menezes D; Birbe RC; Bombonati A; Pavlides S; Lamb R; Sneddon S; Howell A; Sotgia F; Lisanti MP
Cell Cycle; 2012 Dec; 11(23):4402-13. PubMed ID: 23172369
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-378-mediated suppression of Runx1 alleviates the aggressive phenotype of triple-negative MDA-MB-231 human breast cancer cells.
Browne G; Dragon JA; Hong D; Messier TL; Gordon JA; Farina NH; Boyd JR; VanOudenhove JJ; Perez AW; Zaidi SK; Stein JL; Stein GS; Lian JB
Tumour Biol; 2016 Jul; 37(7):8825-39. PubMed ID: 26749280
[TBL] [Abstract][Full Text] [Related]
12. Proteomic Profiling of β-hCG-Induced Spheres in BRCA1 Defective Triple Negative Breast Cancer Cells.
Sengodan SK; Rajan A; Hemalatha SK; Nadhan R; Jaleel A; Srinivas P
J Proteome Res; 2018 Jan; 17(1):276-289. PubMed ID: 29028349
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function.
Kumaraswamy E; Wendt KL; Augustine LA; Stecklein SR; Sibala EC; Li D; Gunewardena S; Jensen RA
Oncogene; 2015 Aug; 34(33):4333-46. PubMed ID: 25417703
[TBL] [Abstract][Full Text] [Related]
14. BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile.
Guney Eskiler G; Cecener G; Egeli U; Tunca B
J Biochem Mol Toxicol; 2019 May; 33(5):e22286. PubMed ID: 30672063
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-155, induced by FOXP3 through transcriptional repression of BRCA1, is associated with tumor initiation in human breast cancer.
Gao S; Wang Y; Wang M; Li Z; Zhao Z; Wang RX; Wu R; Yuan Z; Cui R; Jiao K; Wang L; Ouyang L; Liu R
Oncotarget; 2017 Jun; 8(25):41451-41464. PubMed ID: 28562349
[TBL] [Abstract][Full Text] [Related]
16. Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine.
Nhukeaw T; Temboot P; Hansongnern K; Ratanaphan A
BMC Cancer; 2014 Feb; 14():73. PubMed ID: 24507701
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers.
Boukerroucha M; Josse C; ElGuendi S; Boujemla B; Frères P; Marée R; Wenric S; Segers K; Collignon J; Jerusalem G; Bours V
BMC Cancer; 2015 Oct; 15():755. PubMed ID: 26490435
[TBL] [Abstract][Full Text] [Related]
18. Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents.
Tassone P; Blotta S; Palmieri C; Masciari S; Quaresima B; Montagna M; D'Andrea E; Eramo OP; Migale L; Costanzo F; Tagliaferri P; Venuta S
Int J Oncol; 2005 May; 26(5):1257-63. PubMed ID: 15809716
[TBL] [Abstract][Full Text] [Related]
19. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
20. Decreased miR-206 expression in BRCA1 wild-type triple-negative breast cancer cells after concomitant treatment with gemcitabine and a Poly(ADP-ribose) polymerase-1 inhibitor.
Sasaki A; Tsunoda Y; Tsuji M; Udaka Y; Oyamada H; Tsuchiya H; Oguchi K
Anticancer Res; 2014 Sep; 34(9):4893-7. PubMed ID: 25202071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
